Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SOLAI Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while SOLAI Limited trades at $3.34 (market cap $15.52M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2570.2× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| ALNY | SLAI | |
|---|---|---|
Market Cap | $39.89B | $15.52M |
Sector | Health | Technology |
52-Week High | $491.22 | $30.66 |
52-Week Low | $278.09 | $2.74 |
Enterprise Value | $38.15B | $15.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SLAI trades at $3.34, up 7.05% today, but technical indicators signal a bearish trend with support at $3. The company reported a net loss of $33.88M in 2025, with negative profit margins and ROE. Recent news includes a reverse stock split and a going-private proposal, while the sole analyst coverage is a Hold rating.
The outlook remains highly speculative due to persistent losses and NYSE listing concerns. Risks include financial instability and execution challenges in AI infrastructure. Upside depends on successful acquisitions and product launches, but the stock is suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
